- Omron’s first-quarter net sales missed estimates, reporting 183.71 billion yen versus an estimate of 189.32 billion yen.
- Operating income was higher than expected at 6.27 billion yen, exceeding the estimate of 5.12 billion yen.
- The company reported a net loss of 9.63 billion yen, against an estimated profit of 2.65 billion yen.
- For the full year 2025, Omron maintains its net sales forecast at 825.00 billion yen, below the estimate of 848.56 billion yen.
- The operating income forecast for 2025 is held at 49.00 billion yen, against an estimate of 51.15 billion yen.
- Net income for 2025 is still forecasted at 8.50 billion yen, short of the estimate of 13.8 billion yen.
- The company maintains a dividend forecast of 104.00 yen per share, nearly matching the estimate of 104.09 yen.
- Analyst recommendations include 2 buys, 12 holds, and 0 sells.
A look at Omron Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Omron Corp has a positive long-term outlook with a solid overall performance. With a strong momentum score of 4, the company is showing promising growth potential in the future. Additionally, Omron Corp scores well in resilience, value, and dividend factors, all receiving a score of 3, indicating stability and consistency in its operations and financial performance.
Omron Corp, a manufacturer of electronic components and systems for factory automation, is positioned well to benefit from its diverse product offerings in industrial automation, electronic components, automotive electronics, social systems, and healthcare. Although growth scored a 2, the overall balanced performance across other key factors suggests a steady outlook for the company’s future development and financial health.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
